The data provide impetus for further study to determine if the combination of OAS activation and checkpoint inhibition is of therapeutic relevance for the treatment of breast cancer during pregnancy, or other cancers where a more robust effect of PD-L1 occurs. This evidence concerns the gene CD274 and breast carcinoma.